证券代码：603717 证券简称：天域生物 公告编号：2026-015 天域生物科技股份有限公司 第五届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 自公司披露本次向特定对象发行 A 股股票事项以来，公司与相关中介机构 积极推进各项工作。现综合考虑当前宏观经济环境、资本市场环境变化及公司实 际情况等诸多因素，经与相关各方充分沟通、审慎分析后，公司决定终止本次向 特定对象发行 A 股股票事项并撤回申请文件。具体内容详见公司于同日在上海 证券交易所官方网站和指定信息披露媒体上发布的《关于终止 2025 年度向特定 对象发行 A 股股票事项并撤回申请文件的公告》（公告编码：2026-016）。 表决结果：6 票同意、0 票反对、0 票弃权、0 票回避。 1 本议案已经第五届董事会第三次独立董事专门会议事前审议通过。根据公司 2025 年第三次临时股东大会的授权，本议案无需提交股东会审议。 一、董事会会议召开情况 天域生物科技股份有限公司（以下简称"公司"）第五届董事会第九次会议 （以下简称"本次会议"）通 ...

如何抓住黄金波段机会？聪明钱的选择，黄金+股票一键搞定>> 格隆汇2月11日丨天域生物(603717.SH)公布，自披露本次向特定对象发行A股股票事项以来，公司与相 关中介机构积极推进各项工作。现综合考虑当前宏观经济环境、资本市场环境变化及公司实际情况等诸 多因素，经与相关各方充分沟通、审慎分析后，公司决定终止本次向特定对象发行A股股票事项并撤回 申请文件。公司将持续密切关注资本市场动态，后续根据自身发展需要合理运用多种资本市场工具，助 力公司长期健康发展。 ...

天域生物公告称，公司于2026年2月11日召开相关会议，审议通过终止2025年度向特定对象发行A股股 票事项并撤回申请文件，同意与导云资产签署《附条件生效的股份认购协议之终止协议》。导云资产为 公司实控人罗卫国控制的企业，本次签署终止协议构成关联交易，但不构成重大资产重组。该事项经董 事会审议通过，无需提交股东会。目前公司生产经营正常，签署终止协议不会造成重大不利影响。 ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

格隆汇2月6日丨天域生物(603717.SH)公布，2026年1月，公司销售生猪4.55万头，销售收入5428.77万 元，环比变动分别为16.10%、21.49%，同比变动分别为15.58%、-11.23%。2026年1月末，公司生猪存 栏21.10万头，同比上升24.07%，环比上升3.31%。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）现将 2026 年 1 月养殖业务 主要经营数据公告如下： 一、2026 年 1 月养殖行业主要经营数据 证券代码：603717 证券简称：天域生物 公告编号：2026-014 天域生物科技股份有限公司 2026 年 1 月养殖业务主要经营数据公告 1 月份 销售数量（万头） 销售收入（万元） 期末库存量 当月 累计 当月 累计 （万头） 2025 年 1 月 3.94 3.94 6,115.20 6,115.20 17.01 2025 年 2 月 3.12 7.06 4,270.88 10,386.08 15.14 2025 年 3 月 4.16 11.25 7,047.03 17,433.11 14.00 2025 年 4 月 3.51 14.76 5,932.95 23,366.06 13.32 2025 年 5 月 2.48 17.24 4,038.75 27,404.81 14.14 2025 年 6 月 3.18 20.42 ...

天域生物（603717）(603717.SH)公告，于2026年1月，公司销售生猪4.55万头，销售收入5428.77万元， 环比变动分别为16.10%、21.49%，同比变动分别为15.58%、-11.23%。2026年1月末，公司生猪存栏 21.10万头，同比上升24.07%，环比上升3.31%。 ...

智通财经APP讯，天域生物(603717.SH)公告，于2026年1月，公司销售生猪4.55万头，销售收入5428.77 万元，环比变动分别为16.10%、21.49%，同比变动分别为15.58%、-11.23%。2026年1月末，公司生猪 存栏21.10万头，同比上升24.07%，环比上升3.31%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603717 证券简称：天域生物 公告编号：2026-012 天域生物科技股份有限公司 关于补选第五届董事会非独立董事 及审计委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 天域生物科技股份有限公司（以下简称"公司"）于2026年02月02日召开第五届董事会第八次会议，审议 通过了《关于补选第五届董事会非独立董事的议案》《关于补选第五届董事会审计委员会委员的议 案》。现将有关情况公告如下： 一、补选第五届董事会非独立董事的情况 根据《公司法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号一一 规范运作》和《公司章程》等有关规定，经公司控股股东提名，董事会提名委员会任职资格审查通过， 董事会同意提名梅晓阳女士（简历详见附件）为公司第五届董事会非独立董事候选人，任期自股东会审 议通过之日起至第五届董事会届满之日止。 本次补选董事事项尚需提交公司2026年第二次临时股东会审议。 二、补选第五届董事会审计委员会委员的情况 为确保董事 ...

证券日报网讯 2月2日，天域生物发布公告称，公司第五届董事会第八次会议审议通过，经公司控股股 东提名，董事会提名委员会任职资格审查通过，董事会同意提名梅晓阳女士为公司第五届董事会非独立 董事候选人，任期自股东会审议通过之日起至第五届董事会届满之日止；为确保董事会审计委员会的正 常运作，董事会同意补选董事王泉先生担任公司第五届董事会审计委员会委员，与梅婷女士（主任委 员）、范宏宇先生共同组成第五届董事会审计委员会，任期自本次董事会审议通过之日起至第五届董事 会届满之日止。 （文章来源：证券日报） ...